Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Abstract: A novel T-cell bispecific antibody (TCB), RO7283420, engaging CD3 and the HLA-A2-Wilms tumor protein 1 complex, was evaluated in this phase 1 study to characterize safety and tolerability, determine the maximum tolerated dose (MTD), and recommend a phase 2 dose for patients with relapsed/r...

Full description

Saved in:
Bibliographic Details
Main Authors: Martin Hutchings, Koorosh Korfi, Pau Montesinos, Armando Santoro, Hsin-An Hou, Pilar Martinez-Sanchez, Susana Vives, Sara Galimberti, Tsai-Yun Chen, Marco Frigeni, Sylvain Garciaz, Olga Salamero Garcia, Su-Peng Yeh, Karen Yee, Jordi Esteve, Ashish Bajel, Shaun Fleming, Anne Catherine Bretz, Jan Attig, Min Sun, Sina Nassiri, Tobias Rutishauser, Christian Klein, Y. May Ma, Gabriel Schnetzler, Stephanie Vauleon, Huixin Yu, Teresa Barata, Muriel Richard, Silke Simon, Heather Hinton, Nino Keshelava, Marion Subklewe
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S2950328025000457
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2950328025000457

Similar Items